Latest News From Pharmachem
02 April, 2015
New research shows that paracetamol is ineffective in reducing pain, disability or improving quality of life for patients who suffer from low back pain or osteoarthritis of the hip or knee, and its use may affect the liver. The study published in the British Medical Journal provides new evidence that paracetamol is no better at treating low back pain than a placebo and its effect on osteoarthritis of the hip or knee is too small to be clinically worthwhile
07 April, 2015
The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from August 10th until December 4th, 2015. The program offers mentoring by entrepreneurs and Bayer experts, office space for 100 days at Bayer HealthCare Pharmaceuticals headquarters, and funding of 50,000€.
10 April, 2015
Industry only event - Data Integrity Presentation 22nd April in Radisson SAS Little Island 8am -11am
13 April, 2015
The Irish economy will continue to outperform the rest of Europe and grow by 5.4 per cent this year, Ibec has said.
20 April, 2015
Pre-tax profits at the firm employed by the Government to deliver the material used for the contentious fluoridation of the State's water supply last year jumped by 56pc to €1.16m.
21 April, 2015
A $300m fibre optics cable between New York and Mayo is set to go ahead after the promoters secured a multimillion euro loan and planning permission
22 April, 2015
Further acquisitions, partnerships, and placing marketing personnel in target markets will be central to Ornua’s global sales growth plans.
24 April, 2015
The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in Pharmaceuticals, and immunodiagnostics products driving growth in Diagnostics.
27 April, 2015
It’s been a busy few weeks for US pharma giant Mylan, which reports quarterly earnings today. Firstly, it made a proposal to buy Dublin-based Perrigo, in a deal valued at approximately $29 billion.